Splenectomy and surgical cytoreduction for ovarian cancer
- PMID: 10831343
- DOI: 10.1006/gyno.2000.5800
Splenectomy and surgical cytoreduction for ovarian cancer
Abstract
Objective: The aim of this study was to evaluate the role of splenectomy, as a surrogate marker for aggressive tumor cytoreduction in ovarian cancer, and its impact on patient morbidity and survival.
Methods: A retrospective cohort study of 35 patients who underwent splenectomy for ovarian cancer cytoreduction between August 1986 and May 1998 was performed. Data abstracted from the medical record included patient demographics, preoperative imaging, surgical procedures, tumor distribution, postoperative complications, chemotherapy treatment, and follow-up information.
Results: Splenectomy was performed in 13 patients at the time of primary cytoreduction and in 22 patients at the time of secondary cytoreduction. Preoperative diagnosis of splenic involvement was frequently made prior to secondary surgery, 77.3% compared to 15.4% of primary cases. In addition, parenchymal splenic involvement was more commonly observed at recurrence, 59.1% vs 23.1% at initial presentation. Disease distribution in secondary cytoreduction cases tended to be more focal, macronodular, and have no ascites. Cytoreduction to less than 1 cm disease was achieved in 100% of primary patients and 86% of secondary patients. Major morbidity (pneumonia, PE, sepsis, pancreatitis, MI) occurred in 23.1% of primary patients and 28.6% of secondary patients. Combining splenectomy with other cytoreductive procedures may make splenectomy itself seem more morbid. With a 17-month median follow-up, median progression-free interval was 24 months in primary patients and 14 months in secondary patients. Among secondary patients, median survival time after splenectomy and cytoreduction was 41 months.
Conclusions: Splenectomy at the time of primary and secondary cytoreduction for ovarian cancer can be performed with acceptable morbidity. Secondary cytoreduction patients may be selected preoperatively by their progression-free interval, prior degree of cytoreduction, and macronodular tumor involvement on imaging studies. Identification of splenic involvement allows for appropriate counseling and preoperative preparation.
Copyright 2000 Academic Press.
Similar articles
-
Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.Ann Surg Oncol. 2006 Dec;13(12):1717-23. doi: 10.1245/s10434-006-9048-2. Ann Surg Oncol. 2006. PMID: 16957965
-
Splenectomy as part of cytoreductive surgery in ovarian cancer.Gynecol Oncol. 2006 Aug;102(2):369-74. doi: 10.1016/j.ygyno.2006.03.028. Epub 2006 Apr 24. Gynecol Oncol. 2006. PMID: 16631919 Review.
-
Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.Gynecol Oncol. 2007 Sep;106(3):482-7. doi: 10.1016/j.ygyno.2007.04.006. Epub 2007 Jun 27. Gynecol Oncol. 2007. PMID: 17590420
-
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.Gynecol Oncol. 2001 May;81(2):237-41. doi: 10.1006/gyno.2001.6143. Gynecol Oncol. 2001. PMID: 11330956
-
Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.
Cited by
-
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute.Int J Surg Oncol. 2010;2010:214919. doi: 10.1155/2010/214919. Epub 2010 Jul 25. Int J Surg Oncol. 2010. PMID: 22312486 Free PMC article.
-
Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis.Diagnostics (Basel). 2023 Nov 20;13(22):3484. doi: 10.3390/diagnostics13223484. Diagnostics (Basel). 2023. PMID: 37998621 Free PMC article. Review.
-
Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.Oman Med J. 2015 Sep;30(5):344-52. doi: 10.5001/omj.2015.70. Oman Med J. 2015. PMID: 26421115 Free PMC article.
-
Splenectomy during cytoreductive surgery in epithelial ovarian cancer.Cancer Manag Res. 2018 Sep 12;10:3473-3482. doi: 10.2147/CMAR.S172687. eCollection 2018. Cancer Manag Res. 2018. PMID: 30254490 Free PMC article.
-
Secondary cytoreduction for patients with recurrent ovarian cancer.Curr Oncol Rep. 2005 Nov;7(6):451-8. doi: 10.1007/s11912-005-0010-4. Curr Oncol Rep. 2005. PMID: 16221382 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical